Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Eur J Clin Microbiol Infect Dis ; 43(1): 55-59, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37924444

RESUMEN

Human sapovirus (HuSaV) is a common cause of gastroenteritis worldwide and is responsible for approximately 4% of acute gastroenteritis episodes in Europe. As reported with norovirus, patients with immunocompromised states are at increased risk of developing HuSaV infection, which can lead to persistent diarrhea and chronic viral shedding in some individuals. Chronic infections are incompletely investigated in these patients, and, due to the lack of specific treatment for HuSaV infection, different clinical approaches were carried out in order to provide further evidence on clinical evolution of these patients with different treatments. In this retrospective study, we report five immunocompromised pediatric patients with recurrent diarrhea caused by HuSaV and long-term viral shedding. Stool samples were analyzed by real-time PCR and tested for enteropathogenic viruses and bacteria and protozoa. Among transplant recipients, reduction of immunosuppressant therapy led to clinical improvement and relief of symptoms, maintaining a balance between managing the infection and preventing graft rejection. Nitazoxanide for 14 days was only used in one of these patients, showing to be an effective therapy to achieve reduction in time to resolution of symptoms. Neither nitazoxanide nor modification of immunosuppressant therapy could avoid recurrences. Further investigations are needed to develop new approaches that can both clear the infection and avoid persistent diarrhea in these patients.


Asunto(s)
Infecciones por Adenovirus Humanos , Infecciones por Caliciviridae , Infecciones por Enterovirus , Gastroenteritis , Sapovirus , Humanos , Niño , Lactante , Sapovirus/genética , Estudios Retrospectivos , Infecciones por Caliciviridae/diagnóstico , Gastroenteritis/diagnóstico , Diarrea/diagnóstico , Inmunosupresores , Heces
3.
Clin Microbiol Infect ; 28(2): 260-266, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34147673

RESUMEN

OBJECTIVES: The main goal of this study was to accurately detect azole resistance in species of the Aspergillus fumigatus complex by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). METHODS: Identification of isolates (n = 868) was done with MALDI-TOF MS using both commercial and in-house libraries. To determine azole susceptibility, the EUCAST E.Def. 9.3.2 method was applied as the reference standard. Identification of resistant isolates was confirmed by DNA sequence analysis. Protein spectra obtained by MALDI-TOF MS were analysed to differentiate species within the A. fumigatus complex and to detect azole-resistant A. fumigatus sensu stricto isolates. RESULTS: Correct discrimination of A. fumigatus sensu stricto from cryptic species was accomplished in 100% of the cases applying principal component analysis (PCA) to protein spectra generated by MALDI-TOF MS. Furthermore, a specific peak (4586 m/z) was found to be present only in cryptic species. The application of partial least squares (PLS) discriminant analysis allowed 98.43% (±0.038) discrimination between susceptible and azole-resistant A. fumigatus sensu stricto isolates. Finally, based on PLS and SVM, A. fumigatus sensu stricto isolates with different cyp51A gene mutations were correctly clustered in 91.5% of the cases. CONCLUSIONS: MALDI-TOF MS combined with peak analysis is a novel tool that allows the differentiation of A. fumigatus sensu stricto from other species within the A. fumigatus complex, as well as the detection of azole-resistant A. fumigatus sensu stricto. Although further studies are still needed, the results reported here show the great potential of MALDI-TOF and machine learning for the rapid detection of azole-resistant Aspergillus fumigatus isolates from clinical origins.


Asunto(s)
Aspergillus fumigatus , Azoles , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Aspergillus fumigatus/genética , Azoles/farmacología , Farmacorresistencia Fúngica , Humanos , Pruebas de Sensibilidad Microbiana , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
4.
Med Oral Patol Oral Cir Bucal ; 13(12): E792-5, 2008 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-19047969

RESUMEN

Mucormycosis is a rare oportunistic infection typically described in diabetic patients with a ketoacidotic status, as well as neutropenic patients. The infection is caused by a group of saprophytic fungi of the class Phycomicetes, being the most frequent ones the Rhizomucor, Rhizopus and Mucor. Its hystological findings include vascular trombosis and tissue necrosis, predominantly in the rino-orbito-cerebral area. Even though the frequency of presentation is very low, given its rapid evolution and severe consequences which include a high mortality rate, it is very important to be aware of the main features of the disease and treat it promptly. Although the diagnosis is based on the high clinical suspect, the computed tomography (CT) and the magnetic resonance image (MRI) plays an important role in determining the extension. The patients should receive treatment in a reference hospital so that a multidisciplinary approach is ensured. In this sense, we present a case of rhino-orbito-cerebralmucormycosis in a diabetic patient, recently treated in our Department. A comprehensive review of the literature has been performed to update the physiopathology and diagnosis. Finally, we describe the different treatment options focusing in the surgical approach, as well as the medical treatment with amphotericine and posaconzole.


Asunto(s)
Encefalopatías/microbiología , Complicaciones de la Diabetes/microbiología , Mucormicosis/complicaciones , Enfermedades Nasales/microbiología , Enfermedades Orbitales/microbiología , Anciano , Humanos , Masculino
6.
Rev Esp Quimioter ; 24(4): 263-70, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22173196

RESUMEN

Antifungal treatment in the hematological patient has reached a high complexity with the advent of new antifungals and diagnostic tests, which have resulted in different therapeutic strategies. The use of the most appropriate treatment in each case is essential in infections with such a high mortality. The availability of recommendations as those here reported based on the best evidence and developed by a large panel of 48 specialists aimed to answer when is indicated to treat and which agents should be used, considering different aspects of the patient (risk of fungal infection, clinical manifestations, galactomanann test, chest CT scan and previous prophylaxis) may help clinicians to improve the results.


Asunto(s)
Antifúngicos/uso terapéutico , Enfermedades Hematológicas/complicaciones , Micosis/complicaciones , Micosis/tratamiento farmacológico , Humanos , Leucemia/complicaciones , Micosis/microbiología , Síndromes Mielodisplásicos/complicaciones , Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA